Alkermes Inc.

5 trials 2 recruiting Commercial sponsor

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

2 Recruiting

2 Completed trials

6 Countries active

1 Unique IMPs

100% Results reported

Phase III

Phase II/III

Phase II

Phase III: 1 Phase II/III: 1 Phase II: 3

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Top IMPs

All trials

5 total

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 Pending

2025-523911-13-00 Phase III 4 countries ALKS 2680
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia Recruiting

2025-520981-23-00 Phase II 6 countries ALKS 2680
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia Recruiting

2024-519822-18-00 Phase II/III 6 countries ALKS 2680
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2 Ended

2024-515452-20-00 Phase II 6 countries ALKS 2680
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 Ended

2024-511112-24-00 Phase II 6 countries ALKS 2680

Showing 1–5 of 5 trials

← All sponsors A–Z